ChipDX Developing Colon, Breast, Lung, and Tissue-of-Origin Tests for Affymetrix Arrays | GenomeWeb

By Justin Petrone

Sustained by a recent study that showcased its ability to identify recurrence risk of colon cancer, New York-based molecular diagnostics firm ChipDX is moving ahead with plans to eventually debut at least four microarray-based assays for the clinical market.

CEO Ryan van Laar told BioArray News this week that the two-year-old company currently has in its pipeline tests for colon, breast, lung, and tissue of origin cancer identification.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.